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Abstract 
Alcohol has been suggested to be a risk factor for opioid dependent patients in methadone 
maintenance treatment (MMT). Literature shows that MMT has limited effects on alcohol 
use. Nevertheless, a decrease in alcohol use was detected in the Swiss heroin-assisted 
treatment (HAT) study. In this paper we carry out an in-depth analysis of the German HAT 
trial with the aim of determining whether alcohol use was affected among patients undergoing 
heroin-assisted (HAT) and methadone maintenance treatment (MMT). Analysis was carried 
out using self reported data on consumption units of alcohol used (CU), Addiction Severity 
Index composite scores (ASI CS) and carbohydrate-deficient transferrin (CDT) measures. 
Results suggest significant reduction of CU and CDT in both groups, yet larger effects in the 
HAT group. ASI CS significantly decreased in the HAT but not in the MMT group. The 
greater benefit of HAT in reducing alcohol use may be due to the greater daily frequency of 
dispensing heroin coupled with a requirement of sobriety at each dosing occasion. 
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Alcohol abuse, alcohol dependence, diamorphine, heroin-assisted treatment, methadone 
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Introduction 
Heroin-assisted treatment (HAT) has been implemented in clinical trials in 
Switzerland, the Netherlands, Spain, Germany, United Kingdom and Canada (Fischer et al., 
2007).HAT has shown feasibility, effectiveness and safety in the Swiss, Dutch and Spanish 
trials (March et al., 2006; Rehm et al., 2001; van den Brink et al., 2003). In the German model 
project, HAT users showed better results than methadone maintenance treatment (MMT) in 
terms of health improvement and reduced illicit drug use (Haasen et al., 2007), and these 
results lasted over time (Verthein et al., 2008). 
Concerning alcohol abuse and dependence in HAT patients, few results have been 
published. The Swiss study reported decreasing rates of occasional alcohol use whereas daily 
alcohol use remained approximately constant (Uchtenhagen et al., 1999). No reports of 
treatment effects on alcohol consumption have been published on the Dutch or Spanish HAT 
trials. The British and Canadian trials are currently in progress and no analyses have been 
published yet. 
Effects of MMT on alcohol use have been analyzed in several studies. Srivastava et al. 
(2008) carried out a review of 14 longitudinally designed studies on the effects of MMT on 
alcohol use. Of the articles reviewed, nine found no change, three found an increase and 
another three articles a decrease in alcohol use. According to the authors, the studies that 
found no change or a decrease in alcohol use were stronger methodologically, as they were 
randomized controlled trials and prospective cohorts, whereas the studies that found an 
increase were all retrospective. Thus, although conclusions are complicated to make due to 
the heterogeneity of the reviewed studies, an increase of alcohol use was not considered to be 
probable. Using a two group design, Lollis et al. (2000) carried out a study where opioid 
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dependent patients not in MMT reported significantly more alcohol intake than the group in 
MMT, confirming the hypothesis that patients in MMT are not likely to drink more. 
The extent and reasons to which patients in MMT believed to change their drinking 
behavior during MMT were analyzed by Hillebrand et al. (2001). These authors found 
subjective norms (normative influence by “important others”) and perceived functions of 
alcohol use (such as relaxing or empowering the effect of methadone) to be the strongest 
positive predictors. Bickel et al. (1987) reviewed treatments for alcoholic patients in MMT 
and found reduction both in alcohol and drug consumption in combined behavioural-
pharmacological treatment but not in abstinence oriented, controlled drinking or voluntary 
disulfiram treatment. 
Alcoholism has been suggested to be a relevant health risk factor for patients treated 
with methadone. Alcohol has been found to increase the risk of fatal opiate overdose 
(Hickman et al., 2008; Polettini et al., 1999; Ruttenber et al., 1990). A study carried out with 
100 patients attending treatment showed that those who consumed alcohol had poorer diets 
and smoked more (Best et al., 1998). Another study (el-Bassel et al., 1993) pointed out the 
relationship between alcoholism and psychiatric symptomatology. The authors found higher 
rates of somatization, obsessive-compulsive behavior, depression, phobic anxiety, and 
psychosis in alcohol dependent than in non-dependent MMT patients. The higher prevalence 
of hepatitis C for MMT patients makes those who have an extensive history of alcohol use 
more vulnerable, leading to a poorer prognosis (Sylvestre, 2002) and even causing death 
(Zador and Sunjic, 2000). If treatment is intended, alcohol use can impair the efficacy of 
interferon-based treatments (Cooper and Mills, 2006). The absence of alcohol use has been 
also related to lower criminality in MMT clients (Patterson et al., 2000).  
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Nevertheless, the literature suggests that there are no important interactions between 
alcoholism and MMT outcome. Rowan-Szal et al. (2000) reported no influence of alcohol use 
in an outpatient methadone treatment in terms of session attending and retention rate, even 
though they had lower levels of trust and respect for the counselors than other patients with no 
alcohol abuse. Chatham et al. Chatham (1995) found similar results and suggested that heavy 
drinking clients were significantly more likely to have prior experience with self-help groups 
and therefore, more capable to stay in treatment. 
Considering the importance of addressing alcohol use in the treatment of opioid 
dependence, the effect of HAT compared to MMT on the possible reduction of alcohol use 
was analyzed as a secondary outcome measure in the German HAT trial.  
Materials and methods 
The original German trial sample was composed of 1015 heroin dependent patients, 
either not in treatment in the last 6 months or who were not responding to maintenance 
treatment. This sample was the result of an initial screening of 2083 heroin users, of which 
1272 came to the initial baseline examination, 1032 fulfilled inclusion criteria and were 
randomized. 17 patients dropped out before treatment by withdrawing their consent. Finally 
515 persons were randomized to the HAT group and 500 to the MMT group constituting the 
intention to treat sample (ITT). The treatment duration was 12 months, with 67.2% of HAT 
patients completing study treatment compared with 40.0% of MMT patients. The HAT 
patients received up to three times a day a maximum single intravenous dose of 400 mg of 
diamorphine (=heroin) with a maximum daily dose of 1000 mg (average dose: 442 mg/d). A 
maximum of 60 mg oral methadone was supplied if needed for take-home night use. MMT 
patients received one dose of oral methadone per day, which could be individually adjusted 
according to clinical judgement (average dose: 99mg/d). Methadone was dispensed upon 
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daily attendance of a MMT clinic, take-home doses were only allowed in exceptional cases. A 
breath alcohol test of 0 was required before receiving methadone or diamorphine. 
Psychosocial treatment was also randomized within two groups. Patients received 
psychoeducation plus individual counseling or case management and motivational 
interviewing (for further details on the methodology of the trial see Haasen et al. (2007) and 
Degkwitz et al., (2007). 
Data for the calculation of composite scores (ASI CS) according to the EuropASI 
(Kokkevi and Hartgers, 1995; based on the fifth edition of the Addiction Severity Index by 
McLellan et al., 1992; German version: Gsellhofer et al., 1999), was available for 965 patients 
at baseline (t-1) and 895 at the end of the 12 month period (t12), but only for 849 (ASI 
subsample) both at t-1 and t12. Self reported data on alcohol use in average units per day (CU, 
each unit=20g) was collected for 955 patients at t-1 and 902 at t12, and only for 850 patients 
both at t-1 and t12. Sample size differences are due to missing data.  
As a biological marker of heavy alcohol use, carbohydrate-deficient transferrin (CDT) 
is widely used to monitor alcohol use in treatment (Anton, 2001). In this study it was used as 
an additional measure to assess changes in alcohol use. CDT blood measures were available 
only for part of the sample at t-1 (n=484) and t12 (n=696) and only for 364 (CDT subsample) 
both at t-1 and t12. CDT sample size was considerably smaller due to protocol violations 
(wrong laboratory units at baseline or not having completed CDT analyses in order to save 
costs). Furthermore, an ASI CS threshold of 0.17 for predicting alcohol dependence diagnosis 
has been recommended (Rikoon et al., 2006), while a cut-off of 3% is recommended for 
clinical relevance of CDT (Hock, 2005), both of which were used in this study. 
Outcome was evaluated according to two primary outcome measures (see also Haasen 
et al. 2007): improvement of health and reduction of illicit drug use. Physical and mental 
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health was based on the Opiate Treatment Index (OTI; Darke et al., 1992; 1991) health scale 
and Global Severity Index (GSI) of the Symptom Checklist-90-Revised (SCL-90-R; 
Derogatis, 1994). 
Results 
The main characteristics of the ITT sample and two subsamples can be seen in table 1. 
Regarding sociodemographic characteristics and ASI CS at baseline, the two subsamples are 
fairly comparable to the ITT sample, with only one significant difference between treatment 
groups (HAT or MMT) in years of education in the CDT sample (t=2.33, df=361, p=0.02), 
where there is no difference in the ITT sample or ASI subsample. Main outcome information 
is also provided, with better outcome results for the HAT group in the ITT sample as well as 
in the two subsamples. CDT measures, ASI CS and CU showed significant correlations 
(Pearson, two tailed) both in t-1 and t12 as shown in table 2. 
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Table 1. Characteristics of the sample 
 Original ITT sample 
(n=1015) 
ASI subsample (n=849) CDT subsample (n=364) 
Heroin 
n=515 
Methadone 
n=500 
Heroin 
n=439 
Methadone 
n=410 
Heroin 
n=182 
Methadone 
n=182 
Sociodemographic characteristics 
Male gender (%) 80.0 79.8 81.3 78.3 80.2 81.3 
Age (mean ± SD) 36.2 ± 6.7 36.6 ± 6.8 36.4 ± 6.7 36.7 ± 6.9 36.5 ± 6.3 35.9 ± 7.0 
Education in years 
(mean ± SD) 
9.8 ± 1.8 9.7 ± 1.9 9.9 ± 1.8 9.7 ± 1.9 10.2 ± 1.7 9.7 ± 2.0 * 
Employed (%) 13.6 12.3 13.7 13.2 17.0 15.5 
Stable housing (%) 69.0 69.7 69.9 71.4 72.5 67.4 
Duration of heroin 
misuse (mean ± SD) 
13.6 ± 6.3 13.6 ± 6.3 13.8 ± 6.4 13.6 ± 6.3 13.4 ± 6.4 13.1 ± 6.4 
Selected Addiction Severity Index Composite Scores (ASI CS) at baseline, t-1 
ASI CS for alcohol 
misuse (mean ± SD) 
.12 ± .18 .12 ± .19 .12 ± .19 .12 ± .19 .12 ± .20 .12 ± .20 
ASI CS for drug 
misuse (mean ± SD) 
.52 ±.14 .53 ± .13 .52 ± .14 .53 ± .13 .52 ± .15 .52 ± .13 
ASI CS for legal 
problems (mean ± 
SD) 
.42 ± .27 .53 ± .13 .41 ± .27 .39 ± .27 .42 ± .28 .38 ± .27 
Treatment outcome, t12 
Response in health 80.0 74.0 * 84.1 73.9 *** 84.1 74.2 * 
Response in illicit 
drug use 
85.2 65.8 *** 85.4 65.6 *** 85.2 69.8 *** 
* p<0.05 
*** p<0.001 
Original ITT sample: Original Intention to Treat sample at t-1 
ASI subsample: Patients whose Composite scores could be calculated both in t-1 and t12 
CDT subsample: Patients with available CDT data both at t-1 and t12 
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Table 2. Correlation matrix (Pearson, two tailed) of alcohol measures at t-1 and t12 
 CDT ASI CS CU 
Baseline, t-1 
CDT 1   
CS r=0.400 ***, n=348 1  
CU r=0.248 ***, n=356 r=0.658 ***, n=961 1 
12 Months, t12 
CDT 1   
CS 12 r=0.479 ***, n=339 1  
CU r=0.403 ***, n=348 r=0.701 ***, n=895 1 
 
CDT: Carbohydrate-Deficient Transferrin in % of the total transferrin. 
ASI CS: Addiction Severity Index (ASI) Composite Score. 
CU: Consumption Units of alcohol. 
*** Correlations significant p< 0.001, two tailed. 
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Changes and differences in alcohol use 
Table 3 shows the three measures for alcohol use and the results of independent t-tests 
at t-1 and t12 and repeated measures ANOVAs carried out within treatment groups upon the 
three measures in order to explore time effects and between-group interactions. CDT 
measures showed both time and between-group significant interactions, with a stronger 
reduction in the HAT group. ASI CS had no overall time effect due to the missing reduction 
in the MMT group, but analysis was significant between groups CU reduction can be seen in 
both groups, represented by the overall time effect, but without between group interaction 
despite a greater reduction in the HAT group and significantly lower CU at t12. 
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Table 3. Change in alcohol measures: means, standard deviations, t-tests and repeated measures analysis of 
variances 
  HAT 
(mean ± SD) 
MMT 
(mean ± SD) 
Significance 
T-test between 
treatment groups 
Significance 
RM ANOVA between 
treatment groups 
CDT  n=182 N=182   
t-1 3.06 ± 2.19 2.80 ± 1.52 t=1.379, df=321.8, 
p=0.169 
Time effect:  
Pillai’s Trace=0.081, df=1, 
p=0.000 
 
Between-group interaction:  
Pillai’s Trace=0.019, df=1, 
p=0.009 
t12 2.24 ± 1.2 2.48 ± 1.45 t=-1.769, df=350.5, 
p=0.078 
     
ASI CS  n=439 N=410   
t-1 0.12  ± 0.18 0.12 ± 0.19 t=0.183, df=963, 
p=0.855 
Time effect:  
Pillai’s Trace=0.001, df=1, 
p=0.487 
 
Between-group interaction:  
Pillai’s Trace=0.013, df=1, 
p=0.001 
t12 0.09 ± 0.18 0.13 ± 0.20 t=-2.7, df=852.3, 
p=0.007 
     
CU  n=468 N=438   
t-1 6.67 ± 12.11 7.12 ± 13.67 t=-0.897, df=994, 
p=0.370 
Time effect: Pillai’s 
Trace=0.026, df=1, p=0.000 
 
Between-group interaction:  
Pillai’s Trace=0.002, df=1, 
p=0.136 
t12 4.00 ± 9.27 5.69 ± 11.51 t=-2.182, df=874.5, 
p=0.03 
 
HAT: Heroin-Assisted Treatment group. 
MMT: Methadone Maintenance Treatment group 
t-1: Baseline 
t12: Treatment after 12 months 
RM ANOVA: Repeated measures analysis of variance
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Interaction with treatment outcome 
The overall reduction in ASI CS for alcohol correlated slightly with reduction of ASI 
CS for drug use (r=.145, p<0.001) and ASI CS for legal problems (r=0.152, p<0.001). 17.0% 
of the 696 patients with CDT measures at t12 and 26.1% of the 895 patients with ASI CS at 
t12 fulfilled criteria for alcohol dependence according to the recommended thresholds. Table 
4 shows the different treatment outcomes after splitting the sample according to alcohol 
dependence using the two different thresholds. HAT patients had better outcomes in health 
improvement and in reduction of illicit drug use both for alcohol dependent and non-
dependent patients, with higher odds-ratios in the alcohol dependent sample when using the 
CDT threshold and higher odds-ratios for the non-dependent sample when using the ASI CS 
threshold. 
 Table 4. Treatment outcome according to alcohol dependence (according to ASI CS and CDT thresholds) and treatment groups 
  HAT MMT Total Significance between 
treatment groups 
Total significance (a) 
  N % N % N % OR 95% CI OR 95% CI 
Response in health 
improvement (n, 
%) 
No alcohol 
dependence 
(ASI CS, n=661) 
307 85.8 233 76.9 540 81.7 1.808 1.213-2.695 1.794 1.291-2.493 
 Alcohol 
dependence 
(ASI CS, n=234) 
80 76.9 85 65.4 165 70.5 1.765 0.986-3.158   
 No alcohol 
dependence 
(CDT, n=578) 
266 85.3 197 74.1 463 80.1 2.025 1.336-3.070 2.110 1.442-3.086 
 Alcohol 
dependence 
(CDT, n=118) 
40 85.1 49 69.0 89 75.4 2.566 0.995-6.618   
Response in 
reduction of illicit 
drug use (n, %) 
No alcohol 
dependence 
(ASI CS, n=661) 
255 71.2 161. 53.1 416. 62.9 2.184 1.583-3.011 2.114 1.602-2.789 
 Alcohol 
dependence 
(ASI CS, n=234) 
74 71.2 73 56.2 147 62.8 1.926 1.114-3.331   
 No alcohol 
dependence 
(CDT, n=578) 
219 70.2 152 57.1 371 64.2 1.766 1.253-2.489 1.910 1.395-2.614 
 Alcohol 
dependence 
(CDT, n=118) 
34 72.3 34 47.9 68 57.6 2.846 1.291-6.276   
 
Alcohol dependence (ASI CS): ASI Composite score above 0.17 (26.1% of  n=895). 
Alcohol dependence (CDT): Carbohydrate-Deficient Transferrin % value above 3 (17% of n=696). 
(a) Mantel-Haenszel Test between no alcohol dependence and alcohol dependence groups. 
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To assess the effects of alcohol dependence on health and illegal drug use outcomes at 
the end of treatment in both HAT and MMT groups, binary logistic regressions were carried 
out (results in table 5). Regarding health outcome, when a threshold of CDT over 3 was used, 
only treatment group (=.745, p<.0001) was a reliable predictor of health outcome. When a 
threshold of ASI CS over 0.17 was used, improvement of health was predicted by both factors 
(alcohol dependence by ASI CS: =.576, p<.001; treatment group: =.585, p<.0001). No 
effect of alcohol dependence was detected in illegal drug use outcome both using CDT 
(=.190, p=362) or ASI CS (=-.069, p=.668) as predictors. 
Table 5. Binary logistic regression models for health improvement and illegal drug use outcomes 
 Predictor  Wald 2 df OR 95% CI p  
Response in health 
improvement 
Model 1 (ASI CS over 0.17) 
Treatment group .585 12.122 1 1.794 1.291-2.494 <.0001 
Alcohol 
dependence  
.576 10.627 1 1.780 
1.258-2.517 
.001 
Model 2 (CDT over 3) 
Treatment group .745 14.774 1 2.107 1.441-3.080 <.0001 
Alcohol 
dependence  
.173 .515 1 1.189 0.741-1.910 .473 
 
Response in 
reduction of illicit 
drug use 
Model 1 (ASI CS over 0.17) 
Treatment group .749 28.020 1 2.115 1.603-2.791 <.0001 
Alcohol 
dependence  
-.069 .184 1 .933 .681-1.279 .668 
Model 2 (CDT over 3) 
Treatment group .647 16.311 1 1.910 1.395-2.614 <.0001 
Alcohol 
dependence  
.190 .829 1 1.210 .803-1.822 .362 
  
Alcohol dependence (ASI CS): ASI Composite score above 0.17 (26.1% of n=895). 
Alcohol dependence (CDT): Carbohydrate-Deficient Transferrin % value above 3. (17.0% of n=696). 
Discussion 
This is the first controlled study examining the effect of HAT on alcohol use among 
opioid dependent patients, as well as being a further study on the effect of MMT on alcohol 
use. Previous findings in methodologically stronger studies indicating a potentially positive 
Cite as: Haasen, C., Eiroa-Orosa, F. J., Verthein, U., Soyka, M., Dilg, C., Schäfer, I., & Reimer, J. (2009). 
Effects of heroin-assisted treatment on alcohol consumption: findings of the German randomized 
controlled trial. Alcohol, 43(4), 259–264. https://doi.org/10.1016/j.alcohol.2009.02.007 
 
Page 15 of 21 
effect of MMT on alcohol use was confirmed in part by our study, while HAT seems to have 
a significantly more positive effect of reducing alcohol use.  
The reduction of alcohol use in the HAT group is confirmed by a reduction of CDT 
values, a reduction of ASI composite scores and also a reduction in number of alcohol units. 
In the MMT group there is a reduction of CDT values and number of alcohol units, but ASI 
composite scores were slightly higher at the end of the 12 month treatment period. 
Considering that ASI composite scores include other alcohol related problems, such as days 
intoxicated, the improvement with respect to the secondary measure alcohol use in the MMT 
group is not as clear as in the HAT group. This confirms the findings of the recent review on 
the effects of MMT on alcohol use (Srivastava et al., 2008), with an increase of alcohol use 
being improbable but also insufficient clear evidence of a reduction. 
The stronger effect of HAT on a reduction of alcohol use could be explained on the 
one hand by a global positive effect on health status of the patients, as the primary outcome 
analysis of both mental and physical health showed significant improvement (Haasen et al., 
2007), thereby decreasing the necessity of drinking if a perceived positive function of alcohol 
is expected to be a strong predictor (Hillebrand et al., 2001). When looking at the more severe 
cases of alcohol use, those considered to be alcohol dependent according to ASI composite 
scores and CDT thresholds, it becomes apparent that there is no interaction between 
alcoholism and treatment outcome regarding street heroin use, but there is an interaction with 
health outcomes. Whether it is the reduction of alcohol use that results in better overall health 
outcomes or it is the better health outcomes that lead to a reduction of alcohol use, needs to be 
analyzed in future studies.  
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On the other hand, another main reason which could explain the reduction of alcohol 
use under HAT is the fact that diamorphine as well as methadone were only dispensed if 
patients were sober at that moment, forcing MMT patients to be sober in the mornings (once 
daily dispensing) and HAT patients to be sober up to three times a day. The fact that 
diamorphine needs to be dispensed three times a day (morning, midday and evening) due to 
the shorter half-life, increases the motivation to be sober not just in the morning. In general, 
HAT starts with three times daily dispensing, but most patients reduce their clinic visits to 
twice a day (morning and evening) for convenience reasons, nonetheless demanding 
soberness in the evening. The dispensing schedule therefore is a de facto behavioural 
contingency, and this structuring element seems to have a positive influence on treatment 
effects, similar to the effect in studies on contingency reinforcement in other substance use 
treatments (Rogers et al., 2008; Stitzer and Vandrey, 2008). 
A limitation of the study is the lack of full data for all patients of the ITT sample, 
necessitating analyses of subsamples to determine the effects on alcohol use. However, data 
was missing to the same extent for both HAT and MMT groups. Furthemore, both the 
comparison of demographics of subsamples with ITT sample, showing no major differences, 
and the strong correlations shown between CDT values, ASI composite scores and number of 
drinking units, confirm the validity of the study measures.  
Considering the multi-morbidity of severely opioid dependent patients, a stronger 
focus on secondary measures when evaluating maintenance treatment is of great importance. 
The negative health effect of alcohol use, especially the higher risk of fatal opiate overdose 
under the influence of alcohol (Hickman et al., 2008), therefore stands out as one of the most 
important factors to be addressed. The limited effect of MMT in this special group of patients 
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warrants the introduction of alternatives, and HAT deserves to be considered as such an 
alternative due to the better results shown in this and previous studies.  
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